Application of calcium nebulization for mass exposure to an accidental hydrofluoric acid spill

• Published in: Burns Vol. 46; no. 6; pp. 1337 - 1346
• Main Authors: Choe, Michael Sung Pil, Lee, Mi Jin, Seo, Kang Suk, Kam, Sin, Kim, Keon Yeop, Je, Dongwook, Kim, Seong Hun, Nho, Woo Young, Park, Hong In, Shin, Sujeong, Ryoo, Hyun Wook
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.09.2020
• Subjects: Burns; Calcium gluconate; Chemical hazard release; Hydrofluoric acid; Nebulizer; CRP; Chemical hazard release; Calcium gluconate; PSS; nCG; NR; Hydrofluoric acid; IQR; Burns; Nebulizer; HF; CPK
• DOI: 10.1016/j.burns.2020.02.015
• ISSN: 0305-4179

Respiratory toxicity due to mass HF exposure was treated with a calcium nebulizer. Calcium gel was applied to dermal burns at early phase; however, the nebulizer was used for 2–3 weeks after HF spill. Delayed sequelae were observed after mass exposure to high-concentration HF spill. Detoxification processes and antidote stocks are important for disaster management. To determine the long-term prevalence and characteristics of acute hydrofluoric acid (HF) exposure in 2223 patients during the first 30 months after a mass-casualty exposure, and to confirm the antidotal effect of nebulized calcium on inhalation burns caused by HF. This observational cohort study included patients after an HF spill in the Republic of Korea on September 27, 2012; registered patients were followed until April 2015. We assessed toxic effects, distance from spill, degree of acute poisoning, and the effect of nebulized calcium in HF-exposed individuals. Overall, 2223 patients received emergency management or antidote therapy for 20 days. Seventy-four of 134 patients with dermal toxicity received calcium–lidocaine gel, and 368 individuals with bronchial irritation signs received calcium gluconate via nebulizer nCG. A total 377 ampoules 786 g of calcium gluconate were used in the nCG formulation. Calcium administration did not cause adverse reactions during the observation period. Long-term cohort observation showed that 120 patients (120/2233, 5.4%) returned to medical facilities for management of HF-related symptoms within 1 month; 18 persons (18/1660, 1.1%) returned 1–3 months later with chronic cough and respiratory symptoms; and 3 patients (3/1660, 0.2%) underwent medical treatment due to upper-airway toxic symptoms more than 2 years after HF exposure. Respiratory toxicity after mass exposure to an HF spill was successfully treated by calcium nebulizer. Based on our experience, detoxification processes and the amounts of antidote stocked are important when planning for future chemical disasters at the community level.